Pei-Ling Hsu

6PUBLICATIONS
22CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Major global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 17, 2025
Chemotherapy elevates cell surface PD-L1 and MHC-I expression in apoptotic gastric cancer cells.

You-Syuan Lou, Xu-Chen Liu, Chih-Cheng Cheng

|Jul 19, 2024
Combination of Vismodegib and Paclitaxel Enhances Cytotoxicity via Bak-mediated Mitochondrial Damage in EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Wei-Chen Yeh, Yun-Chieh Tu, Pei-Ling Hsu

|Apr 03, 2024
Repurposing the diuretic benzamil as an anti-osteosarcoma agent that acts by suppressing integrin/FAK/STAT3 signalling and compromising mitochondrial function.

Meng-Chieh Lin, Guan-Yu Chen, Hsin-Hsien Yu

|Feb 13, 2024
Impacts of hyperthermic chemotherapeutic agent on cytotoxicity, chemoresistance-related proteins and PD-L1 expression in human gastric cancer cells.

Bor-Chyuan Su, Guan-Yu Chen, Chun-Ming Yang

|Apr 12, 2023
Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis.

Pei-Ling Hsu, Chun-Wei Chien, Yen-An Tang

|Oct 02, 2020
Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis.

Wan-Ning Li, Kuei-Yang Hsiao, Chu-An Wang

Pageof 1

Frequent Collaborators

4 joint publications

Hsin-Hsien Yu

4 joint publications

Chu-Wan Lee

4 joint publications

Bor-Chyuan Su

3 joint publications

Chih-Cheng Cheng